Skip to main content

Table 3 Incidence of cardiovascular events and stroke in clinical trials of erythropoiesis-stimulating agents

From: 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

  Cardiovascular events Stroke
(/1000 patients year) (/1000 patients year)
CHOIR 51.7 5.4
CREATE 58 7.2
TREAT 76.4 9.5
A21 15.6 2.1
Gonryo (G3–5) 21.8 8.6
  1. The events defined as cardiovascular events in each study were as follows: the events specified as primary endpoints in the CHOIR, CREATE, and TREAT studies; myocardial infarction, cerebral infarction, cerebellar infarction, lung congestion, and heart failure, which were specified as adverse events, in the A21 study; angina, myocardial infarction, heart failure, and stroke in stage G3–5 patients in the Gonryo study